Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GW-01
- Development stage
- Unknown
- Lead developer
- Groovy Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GW-01 (also known as GW01-200) is a first-in-class small molecule inhibitor of Ataxin-2 (ATXN2) that targets the Notch signaling pathway, developed by Groovy Medicine (Gaowei Pharma). Discovered using the company's proprietary AI-driven high-dimensional biology platform, GROOVY, GW-01 is designed to overcome the historical 'undruggable' barriers associated with the Notch pathway by targeting Ataxin-2 to inhibit Notch pathway activation. GW-01 is currently in Phase I clinical trials in both China and the United States for the treatment of advanced solid tumors and hematological malignancies, including esophageal cancer, lung cancer, breast cancer, and leukemia.
02
Targets
ATXN2 (Ataxin-2)
Beyond the preview
Go deeper on GW-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GW-01.